Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges

Jeffrey Glennon, Diane Purper-Ouakil, Mireille Bakker, Alessandro Zuddas, Pieter Hoekstra, Ulrike Schulze, Josefina Castro-Fornieles, Paramala J Santosh, Celso Arango, Michael Kölch, David Coghill, Itziar Flamarique, Maria J Penzol, Mandy Wan, Macey Murray, Ian C K Wong, Marina Danckaerts, Olivier Bonnot, Bruno Falissard, Gabriele MasiJörg M Fegert, Stefano Vicari, Sara Carucci, Ralf W Dittmann, Jan K Buitelaar, PERS Consortium

    Research output: Contribution to journalArticlepeer-review

    21 Citations (Scopus)
    182 Downloads (Pure)


    In children and adolescents with conduct disorder (CD), pharmacotherapy is considered when non-pharmacological interventions do not improve symptoms and functional impairment. Risperidone, a second-generation antipsychotic is increasingly prescribed off-label in this indication, but its efficacy and tolerability is poorly studied in CD, especially in young people with normal intelligence. The Paediatric European Risperidone Studies (PERS) include a series of trials to assess short-term efficacy, tolerability and maintenance effects of risperidone in children and adolescents with CD and normal intelligence as well as long-term tolerability in a 2-year pharmacovigilance. In addition to its core studies, secondary PERS analyses will examine moderators of drug effects. As PERS is a large-scale academic project involving a collaborative network of expert centres from different countries, it is expected that results will lead to strengthen the evidence base for the use of risperidone in CD and improve standards of care. Challenging issues faced by the PERS consortium are described to facilitate future developments in paediatric neuropsychopharmacology.

    Original languageEnglish
    Pages (from-to)1149-60
    Number of pages12
    JournalEuropean child & adolescent psychiatry
    Issue number12
    Publication statusPublished - 15 Dec 2014


    • Adolescent
    • Antipsychotic Agents
    • Child
    • Clinical Trials as Topic
    • Conduct Disorder
    • Europe
    • Humans
    • Pediatrics
    • Pharmacovigilance
    • Psychopharmacology
    • Risperidone
    • Treatment Outcome


    Dive into the research topics of 'Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges'. Together they form a unique fingerprint.

    Cite this